# BridgeBio Oncology Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bridgebio-oncology-therapeutics

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.bridgebio.com/bridgebiooncology/
- Total disclosed funding: $200M
- Latest round: Series B (May 2, 2024)
- Investors on record: 11

## About

Based in the US, BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of small molecule therapeutics targeting RAS and PI3K malignancies. In May 2024, BridgeBio Oncology Therapeutics raised USD 200 million in series B funding co-led by Cormorant Asset Management and Omega Funds, including Deerfield Management, Wellington Management, GV, EcoR1 Capital, Enavate Sciences, Surveyor Capital, Aisling Capital, Casdin Capital, and Longwood Fund. As of 2024, the company is led by its CEO, Eli Wallace.

The company’s pipeline includes BBO-8520, a direct inhibitor of KRASG12C, a genetic mutation implicated in non-small cell lung cancer. The firm enrols patients in the ONKORAS-101 trial for individuals with KRASG12C mutant tumors. The firm is also developing BBO-10203, a PI3Ka: RAS breaker designed to disrupt the interaction between RAS and PI3Ka, thereby inhibiting tumor growth while mitigating the risk of hyperglycemia. In addition, BridgeBio's pipeline also encompasses BBO-11818, a pan-KRAS inhibitor targeting both the active and inactive states of KRASG12X.

The organization plans to use the May 2024 funding to accelerate the development of its precision oncology pipeline and new cancer treatments.

## Funding rounds

- Series B, May 2, 2024, $200M — Aisling Capital, Wellington Management, GV, Surveyor Capital, Omega Funds, Longwood Fund, Casdin Capital, Deerfield Management, EcoR1 Capital, Cormorant Asset Management, Enavate Sciences

## Investors

- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series B
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B
- Surveyor Capital — Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series B
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Enavate Sciences — Series B